Kernal gets $48M to develop easier, cheaper CAR T-cell therapies
Kernal has been awarded up to $48M funding to accelerate the development of KR-402, a next-generation in vivo CAR T-cell therapy.| Multiple Sclerosis News Today
Kernal has been awarded up to $48M funding to accelerate the development of KR-402, a next-generation in vivo CAR T-cell therapy.| Multiple Sclerosis News Today
Telomere damage drives T cell exhaustion. Antioxidants restored their cancer-fighting strength in mice. Tumor environments place heavy stress on immune cells that fight cancer. Limited oxygen, elevated acidity, and other harsh conditions overload mitochondria, the cell’s energy producers, which c| SciTechDaily
Iaso Bio has received clearance from the FDA to start clinical trials to test its CAR T-cell therapy equecabtagene autoleucel in MS patients.| Multiple Sclerosis News Today
